Literature DB >> 17215282

AMPK-mediated inhibition of mTOR kinase is circumvented during immediate-early times of human cytomegalovirus infection.

Sagar B Kudchodkar1, Gregory Q Del Prete, Tobi G Maguire, James C Alwine.   

Abstract

Human cytomegalovirus (HCMV) infection increases synthetic rates in infected cells. The resulting increase in energy utilization could potentially increase the AMP:ATP ratio, causing activation of 5'-AMP-activated protein kinase (AMPK). Activated AMPK promotes inhibition of mammalian target of rapamycin (mTOR) kinase, which could be deleterious to the viral infection. Using the AMPK-activating drug 5-amino-4-imidazolecarboxamide ribose (AICAR), we showed that, by 12 h post-HCMV infection, inhibition of mTOR by AMPK is circumvented. However, growth curves showed that progeny virion production is inhibited when AICAR is added, suggesting other inhibitory effects of AICAR or activated AMPK.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17215282      PMCID: PMC1866081          DOI: 10.1128/JVI.02079-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  9 in total

1.  TSC1/TSC2 and Rheb have different effects on TORC1 and TORC2 activity.

Authors:  Qian Yang; Ken Inoki; Eunjung Kim; Kun-Liang Guan
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-20       Impact factor: 11.205

2.  Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.

Authors:  D D Sarbassov; David A Guertin; Siraj M Ali; David M Sabatini
Journal:  Science       Date:  2005-02-18       Impact factor: 47.728

Review 3.  AMPK, the metabolic syndrome and cancer.

Authors:  Zhijun Luo; Asish K Saha; Xiaoqin Xiang; Neil B Ruderman
Journal:  Trends Pharmacol Sci       Date:  2005-02       Impact factor: 14.819

4.  Replication of wild-type and mutant human cytomegalovirus in life-extended human diploid fibroblasts.

Authors:  W A Bresnahan; G E Hultman; T Shenk
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

5.  Human cytomegalovirus infection alters the substrate specificities and rapamycin sensitivities of raptor- and rictor-containing complexes.

Authors:  Sagar B Kudchodkar; Yongjun Yu; Tobi G Maguire; James C Alwine
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-07       Impact factor: 11.205

Review 6.  Growing roles for the mTOR pathway.

Authors:  Dos D Sarbassov; Siraj M Ali; David M Sabatini
Journal:  Curr Opin Cell Biol       Date:  2005-10-13       Impact factor: 8.382

7.  Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.

Authors:  D D Sarbassov; Siraj M Ali; Do-Hyung Kim; David A Guertin; Robert R Latek; Hediye Erdjument-Bromage; Paul Tempst; David M Sabatini
Journal:  Curr Biol       Date:  2004-07-27       Impact factor: 10.834

8.  Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive.

Authors:  Estela Jacinto; Robbie Loewith; Anja Schmidt; Shuo Lin; Markus A Rüegg; Alan Hall; Michael N Hall
Journal:  Nat Cell Biol       Date:  2004-10-03       Impact factor: 28.824

9.  Human cytomegalovirus infection induces rapamycin-insensitive phosphorylation of downstream effectors of mTOR kinase.

Authors:  Sagar B Kudchodkar; Yongjun Yu; Tobi G Maguire; James C Alwine
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

  9 in total
  44 in total

1.  Enhanced hepatitis C virus genome replication and lipid accumulation mediated by inhibition of AMP-activated protein kinase.

Authors:  Jamel Mankouri; Philip R Tedbury; Sarah Gretton; Mair E Hughes; Stephen D C Griffin; Mark L Dallas; Kevin A Green; D Grahame Hardie; Chris Peers; Mark Harris
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

2.  Human cytomegalovirus induces multiple means to combat reactive oxygen species.

Authors:  Carisa Tilton; Amy J Clippinger; Tobi Maguire; James C Alwine
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

3.  Human kinome profiling identifies a requirement for AMP-activated protein kinase during human cytomegalovirus infection.

Authors:  Laura J Terry; Livia Vastag; Joshua D Rabinowitz; Thomas Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

4.  Mechanical stretch activates mammalian target of rapamycin and AMP-activated protein kinase pathways in skeletal muscle cells.

Authors:  Naoya Nakai; Fuminori Kawano; Ken Nakata
Journal:  Mol Cell Biochem       Date:  2015-05-14       Impact factor: 3.396

5.  Tuberous Sclerosis Complex Protein 2-Independent Activation of mTORC1 by Human Cytomegalovirus pUL38.

Authors:  Yadan Bai; Baoqin Xuan; Haiyan Liu; Jin Zhong; Dong Yu; Zhikang Qian
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

Review 6.  Roles of AMP-activated protein kinase in Alzheimer's disease.

Authors:  Zhiyou Cai; Liang-Jun Yan; Keshen Li; Sohel H Quazi; Bin Zhao
Journal:  Neuromolecular Med       Date:  2012-02-26       Impact factor: 3.843

7.  Human cytomegalovirus infection maintains mTOR activity and its perinuclear localization during amino acid deprivation.

Authors:  Amy J Clippinger; Tobi G Maguire; James C Alwine
Journal:  J Virol       Date:  2011-07-06       Impact factor: 5.103

Review 8.  Viral effects on metabolism: changes in glucose and glutamine utilization during human cytomegalovirus infection.

Authors:  Yongjun Yu; Amy J Clippinger; James C Alwine
Journal:  Trends Microbiol       Date:  2011-05-12       Impact factor: 17.079

9.  Digitoxin Suppresses Human Cytomegalovirus Replication via Na+, K+/ATPase α1 Subunit-Dependent AMP-Activated Protein Kinase and Autophagy Activation.

Authors:  Rupkatha Mukhopadhyay; Rajkumar Venkatadri; Jenny Katsnelson; Ravit Arav-Boger
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

10.  Remodeling mTORC1 Responsiveness to Amino Acids by the Herpes Simplex Virus UL46 and Us3 Gene Products Supports Replication during Nutrient Insufficiency.

Authors:  Elizabeth I Vink; Sora Lee; James R Smiley; Ian Mohr
Journal:  J Virol       Date:  2018-11-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.